文献速递皮肤肿瘤

初级纤毛缺失驱动耐药基底细胞癌从Hedgehog向Ras/MAPK通路转换

Loss of Primary Cilia Drives Switching from Hedgehog to Ras/MAPK Pathway in Resistant Basal Cell Carcinoma.
PubMed 文献 · J Invest Dermatol · 2019-01-29

该研究探讨基底细胞癌(BCC)对Smoothened抑制剂(Smoi)耐药后通路转换的机制,发现耐药BCC中纤毛基因突变负荷增加、初级纤毛减少且Hedgehog(HH)通路激活降低;低HH信号特征的耐药BCC中Ras/MAPK通路激活增加,组织分析证实初级纤毛与Ras/MAPK激活呈负相关,去除初级纤毛可增强Ras/MAPK激活;在HH响应细胞系中激活Ras导致对vismodegib及非经典HH通路抑制剂耐药,并对MAPK抑制剂敏感。

要点

  • 耐药BCC中纤毛基因突变负荷增加,初级纤毛减少,HH通路激活降低。
  • 初级纤毛缺失与Ras/MAPK通路激活呈负相关,去除纤毛可增强Ras/MAPK激活。
  • 激活Ras使HH响应细胞系对vismodegib和非经典HH抑制剂耐药,对MAPK抑制剂敏感。

核心结论

  • 初级纤毛是防止BCC从HH向Ras/MAPK通路转换的重要谱系门控因子。

研究设计与样本

  • 研究比较了Smoi耐药BCC、初治BCC及Gorlin综合征患者BCC的纤毛基因突变负荷、初级纤毛和通路激活状态。
  • 采用基因集富集分析、组织分析和细胞系实验验证通路转换。

主要发现

  • Smoi耐药BCC较初治或Gorlin综合征患者BCC纤毛基因突变负荷增加,初级纤毛减少,HH通路激活降低。
  • 低HH信号特征的耐药BCC中Ras/MAPK通路激活增加。
  • 组织分析证实初级纤毛存在与Ras/MAPK激活呈负相关。
  • 去除BCC中的初级纤毛可增强Ras/MAPK通路激活。
  • 在HH响应细胞系中激活Ras导致对vismodegib及非经典HH通路抑制剂(aPKC和MRTF抑制剂)耐药,并对MAPK抑制剂敏感。

临床怎么用

  • 耐药BCC若出现初级纤毛减少和HH通路激活降低,应考虑Ras/MAPK通路激活可能。
  • 对经典和非经典HH通路抑制剂耐药的BCC,MAPK抑制剂可能有效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Basal cell carcinomas (BCCs) rely on Hedgehog (HH) pathway growth signal amplification by the microtubule-based organelle, the primary cilium. Despite naive tumor responsiveness to Smoothened inhibitors (Smoi), resistance in advanced tumors remains common. Although the resistant BCCs usually maintain HH pathway activation, squamous cell carcinomas with Ras/MAPK pathway activation also arise, and the molecular basis of tumor type and pathway selection are still obscure. Here, we identify the primary cilium as a critical determinant controlling tumor pathway switching. Strikingly, Smoothened inhibitor-resistant BCCs have an increased mutational load in ciliome genes, resulting in reduced primary cilia and HH pathway activation compared with naive or Gorlin syndrome patient BCCs. Gene set enrichment analysis of resistant BCCs with a low HH pathway signature showed increased Ras/MAPK pathway activation. Tissue analysis confirmed an inverse relationship between primary cilia presence and Ras/MAPK activation, and primary cilia removal in BCCs potentiated Ras/MAPK pathway activation. Moreover, activating Ras in HH-responsive cell lines conferred resistance to both canonical (vismodegib) and noncanonical (atypical protein kinase C and MRTF inhibitors) HH pathway inhibitors and conferred sensitivity to MAPK inhibitors. Our results provide insights into BCC treatment and identify the primary cilium as an important lineage gatekeeper, preventing HH-to-Ras/MAPK pathway switching.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Kuonen F, Huskey NE, Shankar G, et al. Loss of Primary Cilia Drives Switching from Hedgehog to Ras/MAPK Pathway in Resistant Basal Cell Carcinoma. J Invest Dermatol. 2019. PMID: 30707899. doi:10.1016/j.jid.2018.11.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。